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Background: Randomized Clinical Trial (RCT) designs range from highly selective resulting in lack of external
validity to more inclusive, requiring large sample sizes to observe significant results. Few publications, however,
have compared excluded to enrolled participants. We aimed to assess our trial’s design based on the effectiveness
versus efficacy continuum using the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool and to
compare included and excluded patients.
Methods: Fifteen members of endocrinology section completed PRECIS for DIVA (D-Vitamin Intervention in VA)
trial; an RCT evaluating vitamin D supplementation in improving dysglycemia in patients with prediabetes.
Retrospective chart review compared subjects excluded (OUT) to those included (IN) in RCT. Student’s t and Chi-
square tests were used to compare continuous and categorical variables. Additionally, multiple logistic regression
was completed.
Results: PRECIS scores were nearly universally pragmatic. 178 patients enrolled in DIVA trial were compared with
178 randomly selected patients excluded from study involvement. There was no significant difference between IN
and OUT for the majority of the continuous and all of the categorical variables. Multivariate logistic regression
identified only the A1c, HDL and Charlson Index as significant predictors of a participant’s inclusion or exclusion.
There was higher HDL (51.3(13.9) versus 44.6(10.1), P = 0.001) and Charlson Index (2.85(1.6) versus 2.2(1.17), P =
0.001) for OUT versus IN groups.
Subanalysis of excluded patients in A1c range 5.7 to 6.9, had lower BMI (30.7(3.4) versus 32(2.7), P = 0.002) but
higher HDL (mg/l: 49.7(11.8) versus 44.6(10.1), P = 0.001) and Charlson index (2.85(1.6) versus 2.2(1.17), P = 0.001)
than included participants. Additionally, there was a trend towards higher rates of cancer (22.9 % versus 12.9 %,
P = 0.033) but less psychiatric problems (56.2 % versus 72.5 %, P = 0.026) and thiazide diuretic use (18.1 % versus
29.8 %, P = 0.034).
Conclusion: DIVA trial design appears to favor broad clinical applicability. The majority of objectively compared
variables did not different between patients included and excluded from this RCT. Advice based on the evidence
from this RCT may be applicable to a larger group of patients than those fitting inclusion/exclusion criteria alone.
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Evidence-based advice depends on randomized clinical tri-
als (RCT). These trials are considered “gold standard” for
the development of guidelines including those for predia-
betes and diabetes prevention and management [1].
RCT vary in their applicability to clinical practice.
Many studies are designed with rigid criteria to identify
a very specific population for a proposed intervention,
which can result in a clinically relevant outcome. These
results, however, are not easily transferrable to a larger
pool of patients who would not have met criteria for in-
clusion. This lack of external validity is cited as the most
frequent criticism of RCTs [2]. Other studies, attempting
to be more inclusive, may fail to identify differences
when more lax selection criteria are utilized.
This difference has been characterized as explanatory
(efficacy) versus pragmatic (effectiveness) design [3]. An
efficacy trial answers the question: “Can the intervention
work?” and therefore it is also referred to as an explana-
tory trial. An effectiveness trial answers the question:
“Does the intervention work when used in normal prac-
tice?” and, therefore, is also called a pragmatic trial [3].
Type 2 diabetes mellitus (T2DM) trials commonly, but
not always, prove “efficacy” of diabetes treatment but
tend to exclude many patients for a variety of reasons.
For example, the VADT (Veterans Affairs Diabetes Trial)
trial screened 20,027 patients but randomized 1,791 (8.9 %)
and excluded 91.1 % [4]. A review of 41 National Institute
of Health (NIH) RCTs noted an average exclusion rate of
73 % [5]. Safety is often cited as the reason for exclusion.
However, pragmatism is lost when nearly 90 % of potential
patients are excluded from evaluation of efficacy and safety
in randomized clinical trials.
There are practically no publications dedicated to the
comparison of patients included to those excluded from
an RCT, and participants and non-participants are rarely
compared [6].
The objective of this study was to assess the D-Vitamin
Intervention in Veteran Administration (DIVA) trial
design based on effectiveness versus efficacy continuum
and to compare patients excluded to those included in
the trial.
Methods
The Pragmatic-Explanatory Continuum Indicator Sum-
mary (PRECIS) tool was created by Thorpe et al. [3].
The tool is intended for use by trial designers who wishto subject their protocol to review in order to evaluate
it for the intended purpose and applicability. Ten
domains are included: eligibility criteria, flexibility of
the experimental and comparison interventions, prac-
titioner expertise of the experimental and comparison
interventions, follow-up intensity, primary outcome,
participant compliance, practitioner adherence and
analysis of the primary outcome. Each domain is graded
from most pragmatic to most explanatory, and graphic-
ally represented by the PRECIS wheel as each of 10
spokes: points near the center represent the more ex-
planatory and points near the rim represent the more
pragmatic characteristics of the domain.
Assessment of DIVA trial design
Application of the PRECIS tool to the DIVA trial was
performed by members of the University of Illinois at
Chicago Endocrinology section. In order to ensure fa-
miliarity with the PRECIS tool, the members of the
endocrinology service were provided the original paper
from Thorpe et al. [3], an example of previous applica-
tion of PRECIS tool to assess trial design [7], and a
sample wheel. The group then attended a brief presen-
tation describing the concept of pragmatic versus ex-
planatory trials and the domains involved in the
PRECIS assessment. Finally, group members were
given a brief review of DIVA trial design, the mini-
abstract describing trial specifics, and were allowed to
ask questions about the design to aid in completion of
their wheel.
In completion of the PRECIS wheel, members were
asked to provide individual numerical assessment of
each domain and to plot their score on the provided
wheel. Numerical assessment of each domain included
10 points with scores near 0 favoring efficacy research
(that is, ideal environment) while scores near 10 favor-
ing effectiveness research (that is, practical setting).
The data was collated, and the average score for each
domain was plotted to obtain the overall assessment.
Retrospective chart review
We performed retrospective chart review to compare
subjects excluded (OUT) to those included (IN) in the
(DIVA Study NCT01375660).
The DIVA study is a randomized, double-blind, pla-
cebo controlled trial aimed at assessing the efficacy of
vitamin D for improving glycemic control. African
Eisenberg et al. Trials  (2015) 16:306 Page 3 of 8American male veterans with prediabetes (hemoglobin
A1c (A1C) 5.7 to 6.4 and no antidiabetes medications)
and hypovitaminosis D (25-hydroxyvitamin D (25OHD)
5 to 29 ng/ml) were randomly assigned to receive 12
months of either ergocalciferol (D2, 50,000 IU weekly)
or placebo. Participants who were diagnosed with dia-
betes during screening or intervention (6.5 to 6.9 %)
were also allowed in the study if they did not need to
take antidiabetic medications and A1c remained <7 %.
The primary outcome is changes in indices of insulin
sensitivity as measured by Oral Glucose Insulin Sensi-
tivity (OGIS) and Matsuda index based on results of
Oral Glucose Tolerance Test (OGTT). Efficacy assess-
ment will be based on intention-to-treat and per-
protocol analyses.
The DIVA trial subjects provided an informed consent
prior to study participation. The study was approved by
the Office for the Protection of Research Subjects
(OPRS) Institutional review Board (IRB) at The Univer-
sity of Illinois at Chicago: IRB #2011-0934.Fig. 1 Exclusion flow sheet for D-Vitamin Intervention in Veterans’ Adminis
patients prescreened, 178 were enrolled and randomized (solid double box).
(dashed double box)Included and excluded participant data collection
Recruitment for the DIVA trial started with 2,067 patients
prescreened from Jesse Brown VA Medical Center
(JBVAMC) electronic medical records for demographic cri-
teria fitting the trial’s design: age, gender and race. Further
screening resulted in majority ineligibility due to the pres-
ence of diabetes, weight/BMI, absence of prediabetes or ad-
vanced chronic medical conditions (Fig. 1). Those included
(total 178 in June 2011) met the following criteria: age 35
to 85 years, BMI 28 to 39 kg/m2, A1C 5.7 to 6.9 % and cir-
culating 25OHD level of 5 to 29 ng/ml. Major exclusion
criteria were as follows: history of kidney stones, hyperpara-
thyroidism, hypercalcemia, sarcoidosis, chronic kidney dis-
ease stage 3b or greater, or significant chronic medical
condition that would interfere with study participation. A
completed CONSORT checklist and flow diagram are
available as supplementary files (see Additional file 1
and Additional file 2).
Of those ineligible for participation, a cohort of patients
was chosen that would match the target population of thetration (DIVA) trial. Reason for ineligibility in dashed boxes. Of the 2,067
An additional 178 of excluded patients were analyzed for comparison
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Of 217 subjects who came for full screening, 39 who were
not randomized for the DIVA trial were included for this
comparison study. Of 1,716 who were initially excluded,
the inclusion and exclusion criteria for the current study
were applied. The exclusions were as follows: type 2 dia-
betes, and ineligible sex or race. The inclusion criteria
were as follows: African American men in whom a blood
level for A1c and 25OHD was available within 12 months
of the initial screening for DIVA trial. Based on exclusions,
1,098 were disqualified (Fig. 1). Of 618 remaining subjects,
an additional 139 were randomly chosen until 178 total
patients were found to match the number of those in-
cluded in the DIVA trial.
Patient charts were reviewed retrospectively and data
was collected from +/− 6mo from the time of initial ex-
clusion (that is, time of prescreening, time of eligibility
determination, withdrawal etcetera). Continuous vari-
able data included: A1C, 25OHD level, estimated glom-
erular filtration rate (eGFR), lipid panel (cholesterol,
LDL, HDL, and triglycerides), AST and ALT measures.
Diagnoses recorded included: hypertension, hyperlipid-
emia, degenerative joint disease, cardiovascular disease,
cancer and psychiatric problems. Additional informa-
tion was collected on use of antihypertensive medica-
tions, thiazide diuretics, statins and vitamin D
supplements. Finally, the age-adjusted Charlson index
was calculated for all 356 patients based on the follow-
ing calculations: 1 point for myocardial infarction, con-
gestive heart failure, peripheral vascular disease,
cerebrovascular disease, dementia, chronic obstruction
pulmonary disease (COPD), connective tissue disease,
peptic ulcer disease, uncomplicated diabetes and mild liver
disease; 2 points for complicated diabetes, moderate to se-
vere chronic kidney disease, hemiplegia, leukemia, lymph-
oma, solid tumor without metastasis;3 points for
moderate to severe liver disease, and 6 points for meta-
static solid tumors or AIDS [8]. Age adjustment added 1
point for every 10 years above age 40.
Blood samples measured specifically for study involve-
ment or as reviewed in electronic medical records retro-
spectively were performed in the clinical laboratory
applying laboratory standards of care and references. The
analytical methods included ion-exchange high perform-
ance liquid chromatography (TOSOH g8 analyzer) for
A1C and immunochemiluminometric assay (ICMA, Dia-
Sorin LIAISON analyzer) for 25OHD.Statistics
PRECIS wheel assessment
Standardized descriptive statistics including measures of
means and standard deviations were calculated for each
point of PRECIS wheel. In addition, visual presentationof the PRECIS wheel from each participant was assessed
qualitatively.
Included and excluded groups for DIVA trial assessment
Before statistical analysis, normal distribution and
homogeneity of the variances were tested. Standardized
descriptive statistics including measures of means and
standard deviations for continuous variables were calcu-
lated. Categorical variables were summarized using the
frequencies of the levels of the variables. Student’s t and
Chi-square tests were used to compare continuous and
categorical variables, respectively, between excluded and
included participants. Statistical significance level was
intended at P < 0.05, with Bonferroni correction for 22
variables setting P < 0.0023, using a two-sided test. A
multiple stepwise logistic regression model was used to
determine the predictors of the outcome included versus
excluded groups, with all other characteristics used as
the covariates. All variable with P < 0.2 from the
ANOVA and Chi-squared test were input, and the step-
wise backward model selection procedure was utilized.
All statistical analyses were performed using SAS 9.2
statistical software (SAS Institute, NC)
Results
The 15-member group completing the PRECIS wheel as-
sessment included three medical students, five endocrin-
ology fellows, four medicine residents, and three
endocrinology attending faculty. Members both involved
(four members) or not directly involved (11 members) in
the study completed the PRECIS assessment of the DIVA
trial. The overall mean score for each domain is shown in
the supplementary table (see Additional file 3). The scores
were nearly universally on the pragmatic end of the
spectrum, near the rim of the wheel (Fig. 2). The eligibility
criteria domain was noted as the most explanatory (closest
to the center), with an average score 6.9. Additionally,
plotted were the most pragmatic and explanatory re-
sponses for each domain (dashed lines) (Fig. 2).
A total of 178 patients who were enrolled and ran-
domized to participate in the DIVA trial between May
2011 and June 2012 were included for this analysis. An
additional 178 patients who were excluded from involve-
ment were randomly selected for in-depth profiling. There
was no statistically significant difference between included
and excluded patients for the majority of continuous and
all of the reviewed categorical variables. There was a noted
higher HDL (51.3 (13.9) versus 44.6 (10.1), P = 0.001) for
excluded compared to included groups (Table 1). Add-
itionally, the Charlson index was higher for excluded par-
ticipants (2.85 (1.6) versus 2.2 (1.17), P = 0.001).
Excluded patients were then sub-classified for com-
parison with study participants in prediabetes or newly
diagnosed diabetes range (A1c range 5.7 to 6.9 %). When
Fig. 2 PRECIS wheel assessment of D-Vitamin Intervention in Veteran’s Administration (DIVA) trial. Mean score of 15 participants for each of
10 domains represented by a blue line. Maximum and minimum score given in each domain represented by outer and inner dotted line
respectively
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BMI (30.7 (3.4) versus 32 (2.7), P = 0.002) but higher HDL
levels (mg/l: 49.7 (11.8) versus 44.6 (10.1), P = 0.001) and
Charlson index (3.11 (1.66) versus 2.2 (1.17), P = 0.001),
when compared with included participants. Additionally,
although not reaching statistical significance, the excluded
group was noted with a trend to higher incidence of can-
cer (22.9 % versus 12.9 %, P = 0.033) but lower incidence
of psychiatric problems (56.2 % versus 72.5 %, P = 0.026)
and thiazide diuretic use (18.1 % versus 29.8 %, P = 0.034)
(Table 1).
The multivariate logistic regression showed that only
the A1c, HDL and Charlson index were significant pre-
dictors of whether a participant would be included or
excluded (Table 2).Discussion
At one extreme, a truly pragmatic trial tests treatment
under real-life circumstances [7]. The results of such a
trial would be presumed applicable to the broadest popu-
lation possible and answer the question of intervention
effectiveness [9]. A truly explanatory trial addresses an
intervention performed under ideal conditions, attempting
to control maximally for confounding variables. Clearly,
no trial fits either of these models perfectly and, therefore,
should be thought of as existing on a spectrum rather
than as simply dichotomized [10].This spectrum, visually represented by the PRECIS
tool, was applied to an ongoing RCT. Our results show
that both observers and study researchers believe the
DIVA study to be a pragmatically designed trial. Al-
though clearly subjective in nature, these results favor
applicability to a broader population.
Several criticisms of this approach could be rendered.
Knowledge of study design/methods is critical to one’s in-
terpretation, but the very process of describing the trial in-
herently skews one’s opinion. Although well intentioned,
bias certainly exists in self-assessment. Members of the re-
view varied in their background and level of training (from
medical student to attending physicians), which would
also impact their ability to accurately assess a trial’s design.
Additionally, the PRECIS tool has been helpful in modify-
ing trial design [11], but has not been well studied as an
assessment tool after trial initiation. Finally, alternative
tools to distinguish efficacy from effectiveness studies
could also have been utilized. Many tools have been pro-
posed in the literature, albeit without clear validation, and
have been utilized for review of already completed trials’
pragmatism [10].
RCTs always provide inclusion and exclusion criteria
aimed at identifying a specific population of interest. This
is requisite from a safety and ethical perspective, but in-
herently reduces broader applicability. Strictly speaking,
applicability to an individual patient can be assessed by
determining if that person would meet inclusion/exclusion
Table 1 Comparison of included and excluded participants
Characteristics Included Excluded P value Excluded A1c 5.7-6.9 % P value
Number of Participants 178 178 105
Continuous, Mean (SD)
Age, yrs 59.1 (6.1) 60.1 (7.7) 62.1 (7.5)
BMI, kg/m2 32.0 (2.7) 31.1 (3.5) 30.7 (3.4) 0.002
A1c, % 6.1 (0.2) 5.8 (0.5) 6.2 (0.3)
25(OH)D, ng/ml 14.3 (5.1) 15.2 (5.5) 16.1 (5.7)
eGFR, mL/min 85.7 (16.1) 87.1 (15.7) 83.4 (14.1)
Cholesterol, mg/dl 182.2 (32.1) 173.3 (32.9) 175.8 (35.4)
LDL, mg/dl 111.9 (27.0) 97.3 (31.2) 101.6 (34.0)
HDL, mg/dl 44.6 (10.1) 51.3 (13.9) 0.001 49.7 (11.8) 0.001
TG, mg/dl 132.8 (59.4) 124.8 (58.7) 122.1 (58.4)
AST, U/L 27.0 (10.3) 31.4 (15.6) 27.0 (11.1)
ALT, U/L 45.8 (14.1) 50.8 (20.7) 47.5 (17.6)
Charlson Index 2.20 (1.17) 2.85 (1.60) 0.001 3.11 (1.66) 0.001
Categorical, N (%)
HTN 121 (68.0) 117 (65.7) 68 (64.8)
Hyperlipidemia 97 (54.5) 84 (47.2) 55 (52.4)
DJD 58 (32.6) 68 (38.2) 45 (42.9)
CVD 29 (16.3) 31 (17.4) 23 (21.9)
Cancer 23 (12.9) 34 (19.1) 24 (22.9)
Psychiatric disorders 129 (72.5) 118 (66.3) 59 (56.2)
Anti-HTN medications 108 (60.1) 103 (57.9) 61 (58.1)
Thiazide diuretic use 53 (29.8) 37 (20.8) 19 (18.1)
Statins 69 (38.8) 61 (34.3) 42 (40.0)
Vit D supplements 30 (17.4) 48 (27.0) 25 (23.8)
P values listed for significant findings compared to included group. Each excluded group was compared to included participants. P value deemed significant at
P < 0.0023 after Bonferonni correction. BMI, body mass index; TG, triglycerides; HTN, hypertension; DJD, degenerative joint disease; CVD, cardiovascular disease






A1c 5.267 2.947, 9.413 <.0001
HDL 0.975 0.959, 0.991 0.0031
Charlson Index 0.701 0.581, 0.845 0.0002
Hyperlipidemia 1.045 0.630, 1.735 0.8639
Cancer 0.544 0.222, 1.333 0.1833
Psychiatric
disorders
0.618 0.362, 1.055 0.0780
Thiazide diuretic
use
0.634 0.362, 1.108 0.1097
Results reflect univariate analysis of 22 identified variables for P values <0.2
then subjected to multiple logistic regression
aBased on stepwise multiple logistic regression analysis for the whole group
(n = 356)
bPredictors are values at baseline
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a population perspective, when large databases of patient
characteristics exist; in centralized healthcare systems in
many European countries. A recent epidemiologic study
reviewed characteristics of 180,590 patients from Scotland
with T2DM, and was able to evaluate inclusion/exclusion
from seven major diabetes trials (ACCORD, ADVANCE,
ProACTIVE, UKPDS 33/34, VADT, RECORD) [12]. When
applied to Scottish diabetic patients, this analysis noted as
few as 5 % of patients would have been included and that
at most only 50 % would meet criteria. However, this ap-
proach may not clearly assess whether patients are statisti-
cally different from study participants by other clinically
relevant variables.
Extensive baseline characteristics of treatment versus
control groups are routinely provided to document simi-
larity prior to intervention. Nearly every RCT presents
clinical and outcome-relevant baseline data as reference
within their results section. However, rarely in the litera-
ture are characteristics of participants who were excluded
Eisenberg et al. Trials  (2015) 16:306 Page 7 of 8from a trial offered for comparison. In the ACTNOW
trial, for example, nearly 1,900 patients underwent OGTT,
extensive medical history, A1c, lipids, and urinary isopros-
taglandins even before they were randomized to interven-
tion versus placebo [13]. These data were not reported but
may be useful for direct comparison with included sub-
jects and to provide a reference for the population from
which the researchers are drawing. The proposed benefit
of providing or analyzing this data may be to identify ob-
jective limitations in applicability of a given trial’s results
or conversely provide support for broader applicability
despite the use of inclusion/exclusion criteria.
Here, we provide clinically relevant data to compare
the large cohort of excluded patients to those enrolled in
a randomized clinical trial. This objective data suggests
that several clinical variables are statistically different be-
tween “In” and “Out” groups. This is not entirely surpris-
ing given that these populations were selected to be
distinct (by inclusion/exclusion criteria). While statistical
significance is important, the clinical significance of these
differences should also be considered.
The excluded group had a higher burden of disease
(by Charlson Index), lower BMI and overall higher HDL
levels. Significant determinants of inclusion/exclusion
into the trial were A1c, HDL level and Charlson index.
These clinical differences are not entirely surprising in
that they favor a “healthier” patient for trial enrollment.
However, excluded participants also had fewer psychi-
atric problems (albeit not significant) and higher HDL
levels, variables that would not be expected to be different.
A potential explanation for the former may be a reflection
of very high prevalence of psychiatric disorders in the vet-
eran population and the frequency of care provided to them
could have led to selection bias (for example, more likely to
observe recruitment information). The explanation for the
later is less clear but may be related to the insulin resistance
and/or metabolically healthy obese phenotype in African
Americans [14, 15].
Although there are some statistically different variables,
the majority of the variables compared (18/22) were not
significantly different between groups. This may suggest
that results from the DIVA trial may in fact be applicable
to a broader population. The PRECIS analysis additionally
supports this assertion in describing the trial as more
pragmatic.Conclusion
Our analysis shows that RCT, an accepted gold standard
for evidence-based advice, has clinically relevant limita-
tions. Although the notion exists that RCT involves highly
selected patients, the comparison of included and ex-
cluded subjects is rarely done or reported in the literature.
RCT vary in their pragmatism, which is important forphysicians to understand regarding limitations of general-
izing results to patients seen in clinical practice.
Analysis of the DIVA study design appears to favor
pragmatic applicability as evidenced by the PRECIS wheel
assessment. In addition, patients included and excluded
from this RCT were similar by the majority of measured
clinical characteristics. Advice based on the evidence from
this RCT may be applicable to a broader population than
simply those patients conforming to inclusion and exclu-
sion criteria.
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